Regentis Biomaterials Raises $15MM for U.S. Pivotal Clinical Trial
Regentis Biomaterials closed a US $15MM Series D investment round. Funds will primarily support a pivotal U.S. clinical trial of GelrinC®, a cell-free implant for the treatment of articular knee cartilage injuries. Feb 10, 2016